一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
重新评估免疫治疗时代全脑放疗在非小细胞肺癌脑转移中的作用：一项回顾性队列研究
英文原题：Re-evaluating the Role of Whole Brain Radiotherapy for Brain Metastases From Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study.
查看英文原题
Re-evaluating the Role of Whole Brain Radiotherapy for Brain Metastases From Non-small Cell Lung Cancer in the Immunotherapy Era: A Retrospective Cohort Study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
单纯 WBRT 获益有限；免疫治疗和 SRS 可提高生存率，应在未来临床实践中优先考虑。
研究思路结论见上方概要
背景
在免疫治疗时代，全脑放疗（WBRT）在非小细胞肺癌（NSCLC）脑转移中的作用日益受到争议，许多研究表明其使用对该患者群体几乎没有益处。
方法
一项回顾性队列研究纳入了2017-2020年诊断为NSCLC并伴有脑转移的患者（n=147）。进行了Kaplan-Meier生存分析和多因素Cox比例风险回归，双侧p值<0.05被认为具有统计学显著性。
结果
中位生存期为9.7个月，自诊断时起的平均生存期为15.9个月。接受免疫治疗的患者生存期为31.5个月，而未接受免疫治疗的患者为14.7个月。接受WBRT+免疫治疗的患者平均生存19.5个月，而仅接受WBRT的患者平均生存10.2个月。免疫治疗（风险比（HR）0.48，p<0.001）和立体定向放疗（SRS）（HR 0.62，p<0.001）与生存改善独立相关。单纯WBRT与较差预后相关。
展开英文摘要原文
BACKGROUND
The role of whole brain radiotherapy (WBRT) in non-small cell lung cancer (NSCLC) brain metastases is increasingly debated in the era of immunotherapy, with much research suggesting that its use provides little benefit for this cohort of patients.
METHODS
A retrospective cohort study included patients diagnosed with NSCLC and brain metastases (2017-2020, n=147). Kaplan-Meier survival analysis and multivariate Cox proportional hazards regression were performed, and a two-tailed p-value of <0.05 was considered statistically significant.
RESULTS
Median survival was 9.7 months, with average survival being 15.9 months from the time of diagnosis. Patients who received immunotherapy lived for 31.5 months, while those who did not lived for 14.7 months. Patients who received WBRT + immunotherapy lived an average of 19.5 months, and those who received WBRT lived an average of 10.2 months. Immunotherapy (hazard ratio (HR) 0.48, p<0.001) and stereotactic radiotherapy (SRS) (HR 0.62, p<0.001) were independently associated with improved survival. WBRT alone was associated with poorer outcomes.
CONCLUSION
WBRT alone provides limited benefit; immunotherapy and SRS improve survival and should be prioritized in future clinical practice.
论文信息
- 作者
- Forster P
- 单位
- Oncology, University Hospital of Wales, Cardiff University, Cardiff, GBR.United Kingdom
- 期刊
- Cureus2026 Jun
- 原文标识
- PubMed 42500752 · DOI 10.7759/cureus.111399
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →